Syndax Pharmaceuticals’ (SNDX), Stock Sinks as Market Gains: What you Should Know

The latest trading session saw Syndax Pharmaceuticals close at $25.62. This is a decrease of -1.16% from the previous day. This change lagged the S&P 500’s daily gain of 1.29%. The Dow gained 0.8% and the Nasdaq (a tech-heavy index) added 10.96%.

Today’s closing bell saw shares of the biopharmaceutical firm having gained 4.43% over the previous month. In that same time, the Medical sector lost 0.64%, while the S&P 500 lost 0.23%.

Wall Street will look for signs of positivity from Syndax Pharmaceuticals in the coming earnings report. Analysts predict that Syndax Pharmaceuticals will report earnings of -$0.65 per shares. This would be a decline of 135.91% year-over-year.

Investors should be aware of any recent changes to Syndax Pharmaceuticals’ analyst estimates. Recent revisions tend reflect the most recent near-term business trends. Positive revisions to estimates reflect optimism among analysts about the company’s future business prospects and profitability.

We found that these changes in estimate are directly related to near-term stock price movements. We have created the Zacks Rank to benefit from this. It is a proprietary model that takes into account these estimate changes and gives an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy), to #5 (Strong Sell). Since 1988, #1 stocks have returned an average +25% annually. In the past 30 Days, our consensus EPS projections moved 6.75% lower. Syndax Pharmaceuticals currently holds a Zacks Rank #1 (Strong buy).

The Medical sector includes the Medical – Biomedical & Genetics industry. The Zacks Industry Rank for this industry is currently 62. This puts it in the top 25% among all 250+ industries.

The Zacks Industry Rank lists the order in which the Zacks Rank of each sector’s individual companies ranks. Our research shows that the top 50 percent of industries are rated higher than the bottom half, by a factor from 2 to 1.

Zacks.com will allow you to track all these stock-moving metrics in the upcoming trading sessions.

Get the most recent Zacks Investment Research recommendations. Download 7 Best Stocks in the Next 30 Days Today Click to get this free report

Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Previous post Vikings K.J. Osborn has appeared in the recent weeks
Next post 7 Bizarre Secrets about King Charles That Prince Harry Discovered from His Bombshell Book